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Background: Mice lacking Foxp3+ regulatory T (Treg) cells develop severe tissue inflammation in lung, skin, and
liver with premature death, whereas the intestine remains uninflamed. This study aims to demonstrate the
importance of Foxp3+ Treg for the activation of T cells and the development of intestinal inflammation.
Methods: Foxp3-GFP-DTR (human diphtheria toxin receptor) C57BL/6 mice allow elimination of Foxp3+ Treg by
treatment with Dx (diphtheria toxin). The influence of Foxp3+ Treg on intestinal inflammation was tested using the
CD4+ T-cell transfer colitis model in Rag−/− C57BL/6 mice and the acute DSS-colitis model.
Results: Continuous depletion of Foxp3+ Treg in Foxp3-GFP-DTR mice led to dramatic weight loss and death of
mice by day 28. After 10 days of depletion of Foxp3+ Treg, isolated CD4+ T-cells were activated and produced
extensive amounts of IFN-γ, IL-13, and IL-17A. Transfer of total CD4+ T-cells isolated from Foxp3-GFP-DTR mice did
not result in any changes of intestinal homeostasis in Rag−/− C57BL/6 mice. However, administration of DTx
between days 14 and 18 after T-cell reconstitution, lead to elimination of Foxp3+ Treg and to immediate weight
loss due to intestinal inflammation. This pro-inflammatory effect of Foxp3+ Treg depletion consecutively increased
inflammatory cytokine production. Further, the depletion of Foxp3+ Treg from Foxp3-GFP-DTR mice increased the
severity of acute dSS-colitis accompanied by 80% lethality of Treg-depleted mice. CD4+ effector T-cells from Foxp3+
Treg-depleted mice produced significantly more pro-inflammatory cytokines.
Conclusion: Intermittent depletion of Foxp3+ Treg aggravates intestinal inflammatory responses demonstrating the
importance of Foxp3+ Treg for the balance at the mucosal surface of the intestine.Background
Immunological tolerance and prevention of autoimmunity
is mediated by two categories of mechanisms – recessive
and dominant [1]. Recessive tolerance is based on cell-
intrinsic mechanisms that include elimination of self-
reactive thymocytes or chronically stimulated peripheral T
cell clones by apoptosis or their inactivation resulting
from anergy induction. dominant tolerance leading to the
prevention of autoimmune responses is mediated by a
specialized subset of immune cells acting to restrain
pathogenic immune responses. Regulatory T cells expres-
sing the forkhead family transcription factor Foxp3 play a* Correspondence: stefan.fichtner@klinik.uni-regensburg.de
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reproduction in any medium, provided the ornonredundant role in maintaining dominant immuno-
logical tolerance. The transcription factor Foxp3 is specific-
ally expressed in regulatory T cells (Treg) and is required
for their development [2-6]. Loss-of-function mutations in
the gene encoding Foxp3 in mice and humans result in a
lack of Treg and in fatal autoimmune pathology beginning
at a very early age and affecting multiple organs [7]. The
identification of mutations in the gene encoding Foxp3 as
the cause of aggressive autoimmunity in human patients
with IPEX syndrome (immunodysregulation, polyendocri-
nopathy, enteropathy, X-linked syndrome) and in the
mutant mouse strain scurfy and the subsequent discovery
of the essential function of Foxp3 in the development of
Treg have provided a genetic foundation for the
phenomenon of Treg-mediated dominant tolerance [8,9].
Although several lymphoid cell subsets exhibit suppressiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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represent the only currently known population of lympho-
cytes acting as dedicated mediators of dominant tolerance,
whose suppressor function is vital for the maintenance of
immune homeostasis. Treg cells suppress immune
responses through a variety of mechanisms including the
production of anti-inflammatory cytokines, direct cell-cell
contact, and by modulating the activation state and func-
tion of antigen-presenting cells [10].
The immune response in the intestine is a tightly con-
trolled balance between innate and adaptive effector
responses and negative regulatory pathways of control
[11-14]. Disruption of this balance by genetic or environ-
mental factors can lead to chronic inflammatory syn-
dromes such as the inflammatory bowel diseases (IBDs).
Foxp3+ Treg play a nonredundant role in immune homeo-
stasis, preventing pathological inflammatory responses to
environmental and self-antigens [10]. Mouse models of in-
testinal inflammation have also pinpointed a key role for
Treg cells in intestinal homeostasis, as illustrated in a
model of T cell–driven colitis induced by the transfer of
naive CD4+ T cells into RAG−/− mice [12-14]. Disease
development can be prevented and cured by transfer of
CD4+CD25+ Treg cells, providing a tractable model to
unravel factors controlling the accumulation and func-
tion of colitogenic T cells and Treg cells in vivo [15].
However, the importance of intrinsic Treg, which are
constantly mediating the balance of the homeostasis at the
mucosal barrier in the colon, for the development of acute
and chronic intestinal inflammation is accepted, yet mech-
anistically rather unclear. In this manuscript we present
data on the effects of Foxp3+ Treg deletion on the develop-
ment of intestinal inflammation in genetically targeted
mice. Intermittent deletion of Foxp3+ Treg resulted in a
general activation of effector T cells without differentiation
in a particular T helper cell subset. Further, deletion of
Foxp3+ Treg built the basis for the development of severe
acute DSS-colitis and chronic T cell-mediated intestinal
inflammation.Methods
Mice
Specific pathogen-free Foxp3-GFP-DTR (C57BL/6)
mice were provided by A. Rudensky (Washington
University/Sloan-Kettering Institute). Foxp3-GFP mice
were kindly provided by M. Oukka (Washington Uni-
versity). Rag1−/− mice were obtained from Jackson La-
boratories (Bar Harbor, ME). Foxp3-GFP-DTR and
Foxp3-GFP mice were housed in the animal facility at
the University of Regensburg. Animal use was
approved by the ethics committee and adhered to the
Laboratory Animal Care Guidelines of the University
of Regensburg.Induction of colitis and deletion of Foxp3+ Treg
Acute DSS-colitis was induced by 5% DSS in drinking
water for 5 days followed by normal drinking water for 2
days. Transfer colitis was induced by intravenous injection
of CD4+CD62L+CD25- cells (2.5 × 10 [5] cells/mouse)
obtained from Foxp3-GFP-DTR mice or Foxp3-GFP mice
into Rag1−/− mice. deletion of Foxp3+ Treg was performed
by IP administration of 10 μgdTx per kg body weight.
Cell isolation and cytokine measurement
CD4+ cells from spleen and mesenteric lymph nodes were
isolated by magnetic bead sorting (Miltenyi Biotec,
Bergisch Gladbach, Germany) and cultured 48h under
stimulation with plate-bound anti-CD3 antibody (10μg/ml)
and soluble anti-CD28 antibody (1μg/ml) (BD Biosciences,
San Jose, California, USA. Cytokine concentrations were
measured by ELISA according to manufacturer’s instruc-
tions. ELISA kits were purchased from BD Biosciences
(San Jose, California, USA).
Immunohistochemistry
Formalin-fixed and paraffin-embedded samples were
deparaffined, rehydrated, and pretreated with 3% hydro-
genperoxide in PBS buffer. Sections were incubated with
anti-Ki-67 antibody (Roche, Mannheim, Germany) for 1h
at room temperature. After incubation with biotin-
conjugated secondary antibody and streptavidin-HRP, posi-
tive signals were visualized by DAB kit (BD pharmingen,
San Jose, California, USA). Paraffin-embedded colon sec-
tions were also cut and then stained with H&E. For calcu-
lation of inflammation indices in treated and control group
of mice, the H&E sections were read by investigators
blinded to the experimental protocol and evaluated accord-
ing to formerly published scoring systems for colitis [16].
Flow cytometry
Mesenteric lymph node cells were isolated and subjected
to flow cytometry. For staining, cells were treated with
monoclonal antibodies to mouse anti-CD3 and anti-CD4
antibody (all from eBiosciences, San Diego, California,
USA), respectively. Foxp3 was detected by the genetically
determined green fluorescent protein. Nonspecific binding
of antibodies was blocked by preincubation with Fcγ-block.
Cells were pretreated with BD Cytofix/Cytoperm (BD
pharmingen, San Jose, California, USA).
Statistical analyses
Before statistical analysis normal distribution was tested
with Kolmogorov-Smirnow-Lilliefors test with p ≤ 0.05
considered as normally distributed. Normal distributed
data was evaluated with standard two-tailed Student´s t-
tests with p-values p ≤ 0.05 considered marginally signifi-
cant. For data not showing a normal distribution we used
Wilcoxon-Mann–Whitney tests for statistical analysis. For
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Significant data sets are labelled with an asterisk (*). We
evaluated the statistics with SPSS Statistics software (SPSS
GmbH Software, Munich, Germany). Graph Pad Prism
was used to calculate the Standard deviation (SD) between
experimental data sets containing equal number of repli-
cates. In the case of different numbers of replicates the
Standard Error of the Mean (SEM) was used.
Results
For the experiments presented in this manuscript we used
Foxp3-GFP-DTR mice on a C57BL/6 background [2,3].
The genome of these mice carries a knock-in cDNA se-
quence encoding the human diphtheria toxin receptor
(DTR) fused to sequences encoding green fluorescent pro-
tein (GFP) and linked with an internal ribosome entry site
(IRES). This sequence is incorporated into the 3’ untrans-
lated region of Foxp3 to produce Foxp3DTR. In these mice
GFP and DTR are only detected in Foxp3+ Treg, not in
Foxp3- effector T cells. To specifically eliminate Foxp3+
Tregdiphtheria toxin (DTx) needs to be administrated IP
to the mice. As previously shown and also corroborated in
preparation for this set of experiments, a single injection of
DTx induced a transient deletion of Foxp3+ Treg for ap-
proximately 48 h with an almost 50% recovery being
achieved 72 h after DTx administration (Additional file 1:
Figure S1). To identify the dose of diphtheria toxin that
induced Foxp3+ Treg deletion, we treated Foxp3-GFP-
DTR mice with 50, 10, 5 or 1 μg DTx per kg body weight
and determined Foxp3+ Treg deletion after 24 h. A more
than 90%downregulation of Foxp3+ Treg could be
observed following the administration of 10 or 50 μg DTx
per kg body weight (data not shown). Therefore we
decided to use 10 μg DTx per kg body weight for our
experiments.
Deletion of Treg leads to weight loss and death
To determine the consequences of ongoing deletion of
Foxp3+ Treg in adult mice, we administered 10 μg DTx
per kg body weight every other day to 3-month-old mice.
Deletion of Foxp3+ Treg induced severe pathology includ-
ing wasting disease, splenomegaly and lymphadenopathy.
The body weight of mice receiving DTx every other day
started to decline a few days after starting Foxp3+ Treg de-
letion and continued to decrease throughout the observa-
tion period (Figure 1A). In addition, further administration
of DTx resulting in permanent deletion of Foxp3+ Treg led
to death of the mice between days 18 and 28 after the be-
ginning of DTx treatment (Figure 1B). Continuous admin-
istration of DTx to Foxp3-GFP mice, which are not
carrying the DTR in their genome and therefore are not
susceptible to Foxp3+ Treg deletion by DTx, showed no
decrease in body weight and no premature death when
compared to control treated Foxp3-GFP-DTR mice. Thus,one can conclude that the administered low dose of DTx
does not induce pathology in immune competent mice
(data not shown).
Deletion of Treg induces inflammation in lung, liver, but
hardly in the colon
In order to demonstrate the effects of Foxp3+ Treg deletion
indifferent organs, we examined histological sections of the
lung, liver and colon after 10 days of continuous Foxp3+
Treg deletion. We found severe infiltration of lymphocytes
and mononuclear cells into the lung interstitium and into
liver sinusoids in mice which have received DTx, in order
to achieve Foxp3+ Treg deletion, when compared to control
treated mice. However, the deletion of Foxp3+ Treg did not
induce lymphocytic and mononuclear infiltration in the
colon as it was if at all minimal (Figure 2A). The results of
the analysis of histological sections led to the assumption
that the cellular proliferation index in the organs of mice
without Foxp3+ Treg was increased. This was corroborated
via immunohistochemical staining of the proliferation mar-
ker Ki-67. As shown in Figure 2B, we found highly
increased proliferation of inflammatory, as well as paren-
chymal cells in the lung and liver of mice lacking Foxp3+
Treg. Similar to the data presented in Figure 2A, the prolif-
eration index in the colon remained unchanged regardless
of the presence or absence of Foxp3+ Treg (Figure 2B).
Deletion of Treg activates CD4+ T cells
To further examine the immunologic consequence of con-
tinuous deletion of Foxp3+ Treg, we isolated CD4+ T cells
from mesenteric lymph nodes and spleens after 10 days of
Foxp3+ Treg deletion. These cells were restimulated to ob-
tain supernatant for T helper cell-derived cytokine detec-
tion. CD4+ T cells from mesenteric lymph nodes of
control-treated Foxp3-GFP-DTR mice and DTx-treated
Foxp3-GFP mice hardly produced any cytokines upon
polyclonal T cell receptor (TCR) stimulation and co-
stimulation. In contrast, CD4+ T cells from mesenteric
lymph nodes of mice without Foxp3+ Treg produced ex-
tensive amounts of IFN-γ, IL-13 and IL-17A (Figure 3A
and Additional file 2: Figure S2). To demonstrate a pos-
sible systemic activation of CD4+ T cells, we isolated those
cells from spleens of control-treated Foxp3-GFP-DTR
mice, DTx-treated Foxp3-GFP mice and DTx-treated
Foxp3-GFP-DTR mice. Similar results, as demonstrated
with cells from mesenteric lymph nodes, could be
obtained with CD4+ T cells from the spleen (Figure 3B
and Additional file 3: Figure S3). The changes seen by the
evaluation of T-cell derived cytokines, could also be veri-
fied for the expression levels of TNF and IL-1β from
CD11b+ cells isolated from the spleen (Additional file 4:
Figure S4). Therefore, deletion of Foxp3+ Treg resulted in
a systemic activation of inflammatory cells to produce a
broad spectrum of proinflammatory cytokines.
Figure 1 Deletion of Foxp3+ Treg leads to weight loss and death. (A) Body weight as a percent of starting weight of PBS-treated and
DTx-treated Foxp3-GFP-DTR mice. DTx was administered every other day until the end of the observation period. Every group initially contained
10 mice. Data shown are representative for 3 independent experiments. Error bars represent the SEM. (B) Kaplan Meier Survival curve of
PBS-treated and DTx-treated Foxp3-GFP-DTR mice. DTx was administered every other day until the end of the observation period. Every group
initially contained 10 mice. Data shown are representative for 3 independent experiments. Log rank test revealed statistical significance with
p=0.0021.
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A chronic T cell-mediated intestinal inflammation can be
induced with the transfer of naïve CD4+CD62L+Foxp3- T
cells into T cell- and B cell-deficient Rag1−/− mice [17-19].
The transfer of those naïve T cells into immunodeficient
mice results in a chronic colitis with wasting disease that is
based on the generation of Th17 cells in the course of the
disease. However, the transfer of total CD4+ T cells (includ-
ing Foxp3+ Treg) or the administration of Foxp3+ Treg
after the transfer of naïve CD4+CD62L+Foxp3- T cells pre-
vents the development of a chronic intestinal inflammation
as the immunologic homeostasis at the mucosal barrier
remains intact. To investigate the effect of the deletion of
Foxp3+ Treg in a situation of intact immunologic homeo-
stasis at the mucosal barrier in the intestine, we reconsti-
tuted Rag1−/− mice with total CD4+ T cells obtained from
Foxp3-GFP-DTR mice and administered DTx (or PBS con-
trol) to those reconstituted animals between days 14 and
18 every other day. Therefore, we could achieve, first, an
intact immunologic homeostasis at the mucosal barrier in
the intestine due to reconstitution with total CD4+ T cells
and, second, a delayed deletion of Foxp3+ Treg. We found
that the administration of DTx between days 14 and 18,
leading to the deletion of Foxp3+ Treg, resulted in an im-
mediate weight loss of mice representing the onset of col-
itis. Control treated mice and DTx treated Rag1−/− mice
after the transfer of CD4+ T cells obtained from Foxp3-
GFP mice continued to increase their body weight until
the end of the observation period (Figure 4A). In accord-
ance with the loss in body weight following the deletion of
Foxp3+ Treg, we observed death of 40% of mice that devel-
oped chronic transfer colitis as a result of Foxp3+ Tregdeletion, whereas all mice with Foxp3+ Treg survived
(Figure 4B). Histologic evaluation showed intestinal inflam-
mation with lymphocytic and mononuclear cell infiltration
in colons of CD4+ T cell (obtained from Foxp3-GFP-DTR
mice)-reconstituted Rag1−/− mice after DTx administra-
tion, whereas control treated mice and Rag1−/− mice after
the transfer of CD4+ T cells obtained from Foxp3-GFP
mice and DTx treatment exhibited no intestinal inflamma-
tion (Figure 4C and Additional file 5: Figure S5). We fur-
ther analyzed the expression of T cell-derived cytokines on
day 49 after T cell transfer. We found a great increase in
IL17A and IFN-γ expression of CD4+ T cells isolated from
mesenteric lymph nodes of mice that received DTx to
delete Foxp3+ Treg when compared to mice without de-
letion of Foxp3+ Treg (Figure 4D and Additional file 6:
Figure S6). The histological changes were limited to the
colon of the mice. Lung and liver did not show any signs
of autoinflammation due to the absence of Foxp3+ Treg
(data not shown).
Deletion of Treg worsens acute intestinal inflammation
The main suppressive effects of Foxp3+ Treg are exerted
onto T helper cells. Therefore, following the investigation
of a colitis model that is completely T cell-dependent, we
extended the experiments to an acute intestinal inflamma-
tion which is mainly due to a breach in intestinal barrier
function. This form of acute colitis can be induced by oral
administration of dextran sulfate sodium in drinking water
(DSS-colitis). In order to induce a severe, acute colitis, we
administered 5% DSS in drinking water for 5 consecutive
days followed by 2 days of regular drinking water. The ter-
mination of the experiment was on day 7 after the onset of
DSS administration. deletion of Foxp3+ Treg in this set of
Figure 2 Deletion of Foxp3+ Treg induces inflammation in lung and liver. (A) Representative H&E staining of lung, liver and colon sections
after 10 days of Foxp3+ Treg deletion. (B) Ki-67 staining of representative lung, liver and colon sections after 10 days of Foxp3+ Treg deletion.
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of DSS and was continued every other day to the end of
the observation period. We could demonstrate that 5%
DSS in drinking water resulted in a weight reduction of
control-treated Foxp3-GFP-DTR mice and DTx-treated
Foxp3-GFP mice of approximately 20% on day 7 after the
beginning of DSS administration. Foxp3+ Treg deletion in
DTx-treated Foxp3-GFP-DTR mice resulted in signifi-
cantly more weight loss when compared to mice with
Foxp3+ Treg. This significant difference was alreadyevident on day 4 after DSS administration and even more
severe on day 7 (Figure 5A). In addition, the severe drop in
body weight apparent in DTx-treated Foxp3-GFP-DTR
mice was associated with 80% mortality in the course of
the short disease, whereas control-treated Foxp3-GFP-
DTR mice and DTx-treated Foxp3-GFP mice showed only
0% and 20% mortality, respectively (Figure 5B). These
results were corroborated by histologic evaluation of H&E
stained colon cross sections. We found severe colitis with
inflammatory cell infiltration in DTx-treated Foxp3-GFP-
Figure 3 Deletion of Foxp3+ Treg activates CD4+ T cells to produce cytokines. (A) IFN-γ, IL-13, and IL-17A production after 10 days of
Foxp3+ Treg deletion. CD4+ cells were extracted from mesenteric lymph nodes and stimulated for 48h. Cytokine concentrations were determined
in culture supernatants by ELISA. Data shown are mean values ± SD and derived from five mice per group each analyzed induplicate. Statistical
significance was analyzed by two-tailed unpaired student´s t-test with a 95% confidence interval. *, p ≤0.05. (B) IFN-γ, IL-13, and IL-17A
production after 10 days of Foxp3+ Treg deletion. CD4+ cells were extracted from the spleen and stimulated for 48 h. Cytokine concentrations
were determined in culture supernatants by ELISA. Data shown are mean values ± SD and derived from five mice per group each analyzed
induplicate. Statistical significance was analyzed by two-tailed unpaired student´s t-test with a 95% confidence interval. *, p ≤0.05.
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Moreover, isolated CD4+ T cells from mesenteric lymph
nodes on day 7 of the acute colitis were restimulated and
IL-17A and IFN- γ were determined by ELISA in the
supernatant. With regards to IL-17A and IFN-γ a great in-
crease in cytokine production could be measured from
CD4+ T cells obtained from DTx-treated Foxp3-GFP-DTR
mice. Whereas, IL-17A and IFN-γ levels from control-
treated Foxp3-GFP-DTR mice and DTx-treated Foxp3-
GFP mice, both groups of mice containing Foxp3+ Treg,
were at low levels (Figure 5D and Additional file 8: Figure
S8). In this acute colitis model in mice with an intact im-
mune system we did not detect histological changes in the
lung and liver due to the absence of Foxp3+ Treg (data not
shown).
Discussion
The immune system is pivotal in mediating the interac-
tions between host and microbiota that shape the intestinal
environment. Intestinal homeostasis arises from a highly
dynamic balance between host protective immunity and
regulatory mechanisms [20]. This regulation is achieved by
a number of cell populations acting through a set of shared
regulatory pathways. Foxp3+ Treg play a nonredundant
role in the maintenance of intestinal homeostasis through
IL-10- and TGF-β1-dependent mechanisms [21,22]. Theiractivity is complemented by other T and B lymphocytes.
To allow for the induction and resolution of host protect-
ive immune responses, Treg development and activity is
tightly linked to the inflammatory response. On the one
hand, Treg control needs to be restrained to allow immune
responses to proceed. On the other hand, Tregs have to
keep pace with ongoing immune responses to restore the
immune balance once inflammation is no longer required.
Indeed, inflammation is often associated with increased
numbers of Tregs. For instance, whereas the number of
Foxp3+ Treg seems to be reduced in the peripheral blood
of patients with IBD, the absolute Treg number seems to
be increased in the mucosa of patients with IBD or celiac
disease, probably as a consequence of the ongoing inflam-
mation [23-29]. However, patients with mutations affecting
the Foxp3 gene develop immune dysregulation, polyendo-
crinopathy, enteropathy, and X-linked syndrome (IPEX).
IPEX is a fatal autoimmune disease starting early in life
and affecting, among other organs, the skin and endocrine
glands. However, the most frequently affected organ is the
intestine, highlighting the importance of Tregs in main-
taining intestinal tolerance [9]. In the mouse, deficiency of
the Foxp3 gene triggers a rapid fatal multi organ auto-
immune disease [2,3]. The time course of specific organ in-
flammation in the mouse seems to be altered in
comparison to the human disease. Probably because of the
Figure 4 Deletion of Foxp3+ Treg is the onset of chronic T cell-mediated intestinal inflammation. (A) Body weight as a percent of starting
weight of PBS-treated and DTx-treated Rag1−/− mice after transfer of total CD4+ cells from Foxp3-GFP-DTR mice or Foxp3-GFP mice. DTx was
administered every other day between days 14 and 18. Each group initially contained of 10 mice. Data are represented as mean ± SEM. (B)
Survival of PBS-treated and DTx-treated Rag1−/− mice after transfer of total CD4+ cells from Foxp3-GFP-DTR mice or Foxp3-GFP mice. DTx was
administered every other day between days 14 and 18. (C) H&E staining and histology score of representative colon sections on day 49 after
transfer of total CD4+ cells from Foxp3-GFP-DTR mice or Foxp3-GFP mice. DTx was administered every other day between days 14 and 18.
Horizontal lines of the scatter plot are mean values derived from five mice per group. The error bars represent the SEM. Each point represents the
histological score of the corresponding mouse. Statistical significance was analyzed by two-tailed unpaired student´s t-test with a 95% confidence
interval. *, p ≤0.05. (D) IFN-γ and IL-17A production of PBS-treated and DTx-treated Rag1−/− mice after transfer of total CD4+ cells from
Foxp3-GFP-DTR mice of Foxp3-GFP mice. DTx was administered every other day between days 14 and 18. CD4+ cells were extracted from
mesenteric lymph nodes and stimulated for 48h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown are
mean values ± SD and derived from five mice per group each analyzed induplicate. Statistical significance was analyzed by two-tailed unpaired
student´s t-test with a 95% confidence interval. *, p ≤0.05.
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tend to develop intestinal inflammation, as they die due to
a severe respiratory insufficiency.
Despite our limited understanding of the role of Foxp3+
Treg in the pathogenesis of human IBD, the ability to alter
regulatory pathways may be a critical avenue for achieving
long-term remission in patients. Results from animal mod-
els suggest that Foxp3+ Treg transfer in patients may be
beneficial. However, most mouse models showing preven-
tion or cure of colitis with Foxp3+ Treg have beenconducted in lymphopenic animals, in which homeostatic
expansion of Foxp3+ Treg may facilitate their impact on
disease. Given that Foxp3+ Treg are already increased in
number in the lamina propria of IBD patients, large num-
bers of transferred Foxp3+ Treg may be required to alter
the balance between a regulatory and a proinflammatory
response. In addition to the high number of Foxp3+ Treg
necessary for cell therapeutic treatment, there is the risk
that Foxp3+ Treg loose their suppressive capabilities in the
course of time. Thus Foxp3+ Treg have been shown to be
Figure 5 Deletion of Foxp3+ Treg worsens acute intestinal inflammation. (A) Body weight as a percent of starting weight of PBS-treated
and DTx-treated Foxp3-GFP-DTR mice and DTx-treated Foxp3-GFP mice. DTx was administered on day −1,day 1, and day 3. (B) Survival of
PBS-treated and DTx-treated Foxp3-GFP-DTR mice and DTx-treated Foxp3-GFP mice. DTx was administered on day −1,day 1, and day 3. (C) H&E
staining and histology score of representative colon sections of PBS-treated and DTx-treated Foxp3-GFP-DTR mice and DTx-treated Foxp3-GFP
mice. DTx was administered on day −1,day 1, and day 3. Horizontal lines of the scatter plot are mean values derived from five mice per group.
The error bars represent the SEM. Each point represents the histological score of the corresponding mouse. Statistical significance was analyzed
by two-tailed unpaired student´s t-test with a 95% confidence interval. *, p ≤0.05. (D) IFN-γ and IL-17A production of PBS-treated and DTx-treated
Foxp3-GFP-DTR mice and DTx-treated Foxp3-GFP mice. DTx was administered on day −1,day 1, and day 3. CD4+ cells were extracted from
mesenteric lymph nodes and stimulated for 48 h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown are
mean values ± SD and derived from five mice per group each analyzed induplicate. Statistical significance was analyzed by two-tailed unpaired
student´s t-test with a 95% confidence interval. *, p ≤0.05.
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exFoxp3 nonTreg which could presumably have deleteri-
ous effects in vivo [30,31]. There is clearly a substantial
need to gather more information about the role of Foxp3+
Treg for the intestinal homeostasis and the development of
intestinal inflammation.
In order to determine the actual involvement of a reduc-
tion in Foxp3+ Treg for the development of an intestinal
inflammation, we used the possibility to specifically delete
Foxp3+ Treg in a genetically determined mouse model.The Foxp3-GFP-DTR mouse itself is immunocompentent
and does not show any inflammatory phenotype per se
[2,3]. With this tool in hand, we could eliminate Foxp3+
Treg from a mouse with an initially intact intestinal
homeostasis and barrier function initially. As expected, we
could demonstrate that the elimination of Treg from mice
with intact mucosal homeostasis led to the onset and ag-
gravation of colitis.
The actual effect of Foxp3+ Treg deletion on the devel-
opment of an intestinal inflammation is of utmost
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the treatment of human IBD, as medication is known to
influence the distribution and function of Foxp3+ Treg.
Saruta et al. have shown that the use of 6-mercatopurine
and azathioprine, but not steroids or anti-TNF agents, was
correlated with lower peripheral numbers of Treg [32].
Moreover, in patients with rheumathoid arthritis, studies
have demonstrated defective suppressor function of per-
ipheral blood Treg that normalized following Infliximab
therapy [33,34]. A recent small study in children with
Crohn´s disease showed increased Foxp3+ Treg in the
colon of patients receiving Infliximab compared to those
receiving other medications [35]. Additionally, the pro-
biotic VSL#3 increases the number of Foxp3+ Treg in the
lamina propria of ileal pouches in patients with pouchitis
[36]. These studies suggest a potential role for Treg modu-
lation in anti-TNF and probiotic therapy.
One major unanswered question is why inflammation
persists in patients with active IBD despite high numbers
of Foxp3+ Treg. Certainly, it is possible that in states of in-
flammation, when Foxp3+ Treg are recruited to or gener-
ated in the intestinal mucosa, there is a relative deficiency
of these cells resulting in incomplete control of inflamma-
tion. However, it is also likely that both in vitro assays and
murine models underestimate complexities in the regula-
tion of the human intestinal milieu. In this environment,
diverse responses to cytokines or costimulatory interac-
tions may modify Foxp3+ Treg suppressive capabilities. To
this end, IL-23, an inflammatory cytokine implicated in the
pathogenesis of IBD in mice and humans, has recently
been shown to inhibit the generation of Foxp3+ Treg in
the colon [37-42]. Additionally, both murine and human
Treg express toll-like receptors (TLR) and are therefore
subject to regulation by pathogens that may alter their
in vivo function. TLR signalling can result in either aug-
mented (TLR 4 and TLR5) or abrogated (TLR8 and TLR9)
Foxp3+ Treg-mediated suppressor function depending on
the ligand engaged [43].
Conclusion
Intermittent depletion of Foxp3+ Treg aggravates intestinal
inflammatory responses demonstrating the importance of
Foxp3+ Treg for the balance at the mucosal surface of the
intestine. From the literature and the data presented in this
manuscript, one can conclude that Foxp3+ Treg inherit an
important role for the establishment if intestinal homeosta-
sis and for the control of intestinal inflammation. Future
cell therapeutic strategies using Foxp3+ Treg seem to be a
promising treatment option for patients with IBD. How-
ever, until then the complex interplay between Foxp3+
Treg and mucosal immunity needs to be further elucidated
in order to prevent unexpected negative effects of this
strategy.Additional files
Additional file 1: Figure S1. Representative flow cytometric analysis
of the Tregs of Foxp3-DTR-GFP mice treated with diphteriatoxin
after 0, 24 and 72 hours after DTx administration.
Additional file 2: Figure S2. Deletionk of Foxp3+ Treg activates
CD4+ T cells to produce cytokines. (A) IFN-γ, IL-13, and IL-17A
production after 10 days of Fox3+ Treg deletion.
CD4+ cells were extracted from mesentric lymph nodes and stimulated
for 48h. Cytokine concentrations were determined in culture
supernatants by ELISA. Data shown are the tabular representation of the
mean values ± SD of the concentration of the distinct secreted cytokines
derived from five mice per group each analyzed in duplicate. (B)
Comparison of the Foxp3-GFP-DTR mice treated with DTx versus the tow
different control groups. Data shown are the corresponding p values
analyzed by a two-tailed unpaired student’s t-test with a 95% confidence
interval.
Additional file 3: Figure S3. Deletion of Foxp3+ Treg activates CD4+
T cells to produce cytokines. (A) IFN-γ, IL-13, and IL-17A production
after 10 days of Foxp3+ Treg deletion. CD4+ cells were extracted from the
spleen and stimulated for 48h. Cytokine concentrations were determined
in culture supernatants by ELISA. Data shown are the tabular
representation of the mean values ± SD of the concentration of the
distinct secreted cytokines derived from five mice per group each
analyzed in duplicate. (B) Comparison of the IFN-γ, IL-13, and IL-17A
production of CD4+ cells isolated from Fox p3-GFP-DTR mice treated
with DTx versus the two different control groups. Data shown are the
corresponding p values analyzed by a two-tailed unpaired student’s t-test
with a 95% confidence interval.
Additional file 4: Figure S4. Deletion of Foxp3+ Treg activates
CD11b+ cells to produce cytokines. (A-B) TNF and IL-1β production 10
days of Foxp3+ Treg deletion. CD11b+ cells were extracted from the
spleen.Cytokine concentrations were determined in culture supernatants
by ELISA. Data shown are the mean values ± SD from five mice per
group analyzed duplicate. (C) Data shown are the tabular representation
of the mean values ± SD of the concentration of the distinct secreted
cytokines derived from five mice per group each analyzed in duplicate.
(D) Comparison of the TNF and IL-1β production of CD11b+ cells
isolated from Foxp3-GFP-DTR mice treated with DTx versus the two
different control groups. Data shown are the corresponding p values
analyzed by a two-tailed unpaired student’s t-test with a 95% confidence
interval.
Additional file 5: Figure S5. Deletion of Foxp3+ Treg is the onset of
chronic T cell-mediated intestinal inflammation. (A) Histology score of
colon sections on day 49 after transfer of total CD4+ cell from Foxp3-
GFP-DTR mice of Fox3-GFP mice. DTx was administered every other day
between days 14 and 18. Tabular representation represents the mean
values ± SEM derived from five mice per group. (B) Comparison of the
histology score from Foxp3-GFP-DTR mice treated with DTx versus the
tow different control groups. Data shown are the corresponding p values
analyzed by a two-tailed unpaired student’s t-test with a 95% confidence
interval.
Additional file 6: Figure S6. Deletion of Foxp3+ Treg is the onset of
chronic T cell-mediated intestinal inflammation. (A) IFN-γ and IL-17A
production of PBS-treated and DTx-treated Rag1−/− mice after transfer of
total CD4+ CELLS FROM Foxp3-GFP-DTR mice of Foxp3-GFP mice. DTx
was administered every other day between days 14 and 18. CD4+ cells
were extracted from mesenteric lymph nodes and stimulated for 48h.
Cytokine concentrations were determined in culture supernatants by
ELISA. Data shown are the tabular representation of the mean values ±
SD of the concentration of the distinct secreted cytokines derived from
five mice per group each analyzed in duplicate. Statistical significance
was analyzed by two-tailed unpaired student’s t-test with a 95%
confidence interval. *,p≤0.05. (B) Comparison of the IFN-γ and IL-17A
production of CD4+ cells isolated from Foxp3-GFP-DTR mice treated with
DTx versus the two different control groups. Data shown are the
corresponding p values analyzed by a two-tailed unpaired student’s t-test
with a 95% confidence interval.
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http://www.biomedcentral.com/1471-230X/12/97Additional file 7: Figure S7. Deletion of Foxp3+ Treg worsens acute
intestinal inflammation. (A) Histology score of colon sections of PBS-
treated and DTx-treated Foxp3-GFP mice. DTx was administered on day-
1, day 1, and day 3. Tabular representation represents the mean values ±
SEM derived from five mice per group. (B) Comparison of the histoslogy
core from Foxp3-GFP-DTR mice treated with DTx versus the two different
control groups. Data shown are the corresponding p values analyzed by
a two-tailed unpaired student’s t-test with a 95% confidence interval.
Additional file 8: Figure S8. Deletion of Foxp3+ Treg worsens acute
intestinal inflammation. (A) IFN-γ and IL-17A production of PBS-treated
and DTx-treated Foxp3-GFP-DTR mice and DTx-treated Foxp3-GFP mice.
DTx administered on day-1, day 1, and day 3. CD4+ cells were extracted
from mesentric lymph nodes and stimulated for 48h. Cytokine
concentrations were determined in culture supernatants by ELISA. Data
shown are the tabular representation of the mean values ± SD of the
concentration of the distinct secreted cytokines derived from five mice
per group each analyzed in duplicate. Statistical significance was
analyzed by two-tailed unpaired student’s t-test with a 95% confidence
interval, *,p≤0.05. (B) Comparison of the IFN-γ and IL-17A production of
CD4+ cells isolated from Foxp3-GFP-DTR mice treated with DTx versus
the two different control groups. Data shown are the corresponding p
values analyzed by a two-tailed unpaired student’s t-test with a 95%
confidence interval.
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